Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Novartis India

NOVARTIND
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Novartis India Share price and Fundamental Analysis

View All Details
View All Details
Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates in four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health.
Company Incorporation1947
ChairmanC Snook
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
2,495.87
PE Ratio
24.73
Industry P/E
34.24
PEG Ratio
1.34
ROE
12.85%
ROCE
16.6%
ROA
10.65%
Total Debt (Cr)
5.06
Debt to Equity
0.01
Dividend Yield
2.47%
EPS
40.87
Book Value & P/B
317.92 x 3.18
Face Value
5
Outstanding Shares(Cr)
2.47
Current Ratio
5.32
EV to Sales
5.27

Included In

+More

Stock Returns

1 Week+1.19%
1 Month-6.54%
6 Months+7.2%
1 Year-8.44%
3 Years+50.58%
5 Years+80.36%
no_data

No Stocks

Smart Score

2.8
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 70.68%

FIIs : 0.19%

DIIs : 0.53%

Public : 28.60%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Novartis India Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Novartis India Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates in four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health.

The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics.

During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in the world, was opened in Horsham (UK) in 2001 and also during the same year Novartis had entered into a partnership with the WHO to stem the spread of malaria in areas of the world were the diseases in endemic.

The Glivec, a drug was launched by the company in April of the year 2002 in India. The Company bagged TERI corporate social responsibility award for the year 2002-03. Novartis united its generics businesses under one single global brand in the name of Sandoz during the year 2003 and also in the same year, the company was granted Exclusive Marketing Rights (EMR) for Glivec. In the year of 2005, the company and Astex Therapeutics formed an alliance to focus on novel cell cycle anti-cancer drugs and also NIL had debuted Citro-macalvit & Trioptal as new products for the year.

During the year 2006 alone Novartis had spent about USD 755 million on research into neglected diseases and various patient-access programs. In August of the same year 2006, the company had filed a petition in the Madras High Court challenging the rejection of the Glivec patent and the same petition was dismissed by the Madras high court in August of the year 2007. In the identical year of 2007, NIL sold its Medical Nutrition business to Nestle. The Company had launched a new marketing initiative on National scale in September of the year 2008 named Arogya Parivar targeting the healthcare needs of villagers.

New products and line extensions introduced during the period 2009-10 were Relmus , Coderan for Pain & Inflammation, Vinlep for Epilepsy and Givec HGC 100 mg for Oncology. Otrivin was re-launched as an OTC remedy in a new spray format and positioned as a convenient alternative to tablets.

During the period 2013-14, the Company signed a Distribution Agreement with Nutri-Ad International NV, Belgium, for marketing and distribution of their poultry feed supplements in India and started distributing Adimix 30 Coated, Eurotiox 32 Premix, Salmonil Dry, Toxynil Dry and Nutrilac IGA. The Company also signed a Marketing and Distribution Agreement with Johnson and Johnson Limited, India, for marketing and distribution of their Ethicon sutures under the brand names Mersutures Catgut 1, Ethilon Nylon and Mersilk Silk for veterinary use in the cattle and canine segments.

Novartis India Share Price

Novartis India share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Novartis India Market Cap

Market capitalization of Novartis India indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Novartis India is valued compared to its competitors.

Novartis India PE Ratio

Novartis India PE ratio helps investors understand what is the market value of each stock compared to Novartis India 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Novartis India PEG Ratio

The PEG ratio of Novartis India evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Novartis India ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Novartis India generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Novartis India ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Novartis India in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Novartis India Total Debt

Total debt of Novartis India shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Novartis India Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Novartis India compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Novartis India CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Novartis India over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Novartis India Technical Analysis

Technical analysis of Novartis India helps investors get an insight into when they can enter or exit the stock. Key components of Novartis India Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Novartis India shares often struggle to rise above due to selling pressure.

Novartis India Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Novartis India ’s financial health and profitability.

Novartis India Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Novartis India Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Novartis India Financials

The financials of Novartis India provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Novartis India Profit and Loss Statements

The profit and loss statement of Novartis India highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Novartis India .

Novartis India Balance Sheet

The balance sheet presents a snapshot of Novartis India ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Novartis India Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.